What is the treatment of selumetinib? How well
Selumetinib is a MEK1/2 inhibitor targeted drug mainly used to treat type 1 neurofibromatosis (NF1) - related plexiform neurofibromatosis. It inhibits tumor growth by blocking the MAPK signaling pathway and has been clinically shown to significantly reduce tumor volume and improve related symptoms.
1. Main therapeutic indications
(1) Type 1 neurofibromatosis: suitable for symptomatic, non-surgical treatment of plexiform neurofibromatosis in NF1 patients aged 2 years and above.
(2) Extended indications: Used in clinical trials for solid tumors with abnormal RAS/RAF pathways, including low-grade serous ovarian cancer.
2 Pharmacological mechanism of action
(1) Targeted inhibition: Selective inhibition of MEK1 and MEK2 kinase activity, precise blockade of MAPK signaling pathway.
(2) Treatment principle: By inhibiting abnormally activated pathways, tumor cell proliferation is reduced and apoptosis is induced.
3 Clinical efficacy data
(1) Tumor response rate: Key trials have shown an overall response rate of 66%, which can sustainably reduce tumor volume.
(2) Symptom improvement: It can effectively alleviate tumor related symptoms such as pain and motor dysfunction.
(3) Long term effect: Some patients can achieve stable tumor control for several years.
4 Drug Characteristics
(1) Formulation advantage: As an oral preparation, it has high convenience for patients to take medication.
(2) Targeted properties: Accurately targeting MEK targets, reducing non-specific side effects.
(3) Breakthrough significance: It is the first targeted therapy drug approved for NF1 plexiform neurofibromatosis.
Disclaimer：《What is the treatment of selumetinib? How well》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！